Pantoprazole sodium hydrate - CAS 164579-32-2
Catalog number: 164579-32-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H14F2N3NaO4S
Molecular Weight:
405.35
COA:
Inquire
Targets:
Proton Pump
Description:
Pantoprazole sodium hydrate is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorates peptic ulcer or irritation of the gastrointestinal tract.
Purity:
>98%
Appearance:
White crystalline powder
Synonyms:
sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;hydrate BY 1023 BY-1023 pantoprazole pantoprazole sodium Protonix SK and F 96022 SK and F-96022 SKF-96022
Solubility:
H2O > 20 mg/ml
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -54℃ for long term (months to years).
MSDS:
Inquire
Quality Standard:
USP EP
Shelf Life:
2 years
Quantity:
Grams-Kilos
InChIKey:
CGJRLPRCWSHOFU-UHFFFAOYSA-N
InChI:
1S/C16H14F2N3O4S.Na.H2O/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;/h3-7,15H,8H2,1-2H3;;1H2/q-1;+1;
Canonical SMILES:
COC1=C(C(=NC=C1)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC(F)F)OC.O.[Na+]
1.Hemopericardium under dabigatran for stroke prevention in atrial fibrillation.
Stöllberger C1, Heger M, Finsterer J. Blood Coagul Fibrinolysis. 2016 Mar 4. [Epub ahead of print]
Spontaneous hemopericardium is a complication of anticoagulant therapy with not only vitamin-K-antagonists, but also with nonvitamin-K-antagonist oral anticoagulants. We report a polymorbid 75-year old male under a therapy with dabigatran, valsartan, amlodipine, nicorandil, furosemide, atorvastatin, bisoprolol, metformin, tizanidine, pantoprazole, and tramadol. He suffered from chest pain for 4 months. Coronary angiography showed only ectatic coronary arteries. He started taking nonsteroidal anti-inflammatory drugs. He was hospitalized because of dyspnea starting 10 days before admission, melena, and renal failure. Hemopericardium was diagnosed and pericardiocentesis yielded 2000 ml hemorrhagic fluid. Review of previous echocardiograms showed a 4 mm echo-free space, epicardial fat or pericardial effusion. A small (<10 mm) echo-free space in a patient on anticoagulant therapy should not be considered as trivial, but additional imaging studies should be carried out.
2.Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.
Dore MP1, Soro S, Rocchi C, Loria MF, Bibbò S, Pes GM. Medicine (Baltimore). 2016 Apr;95(15):e3411. doi: 10.1097/MD.0000000000003411.
Clinical studies have shown that bismuth-containing quadruple therapy given twice a day for 10 to 14 days is effective and safe in the treatment of Helicobacter pylori infection in Sardinia. However, bismuth is no longer available in Italy.To report the effectiveness and tolerability of pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg given b.i.d. (with the midday and evening meals) for 10 days supplemented with Lactobacillus reuteri (DSM 17938) 10 cfu/tablet once a day for 20 days in patients treated in a routine daily practice setting.H pylori infection was defined as a positive gastric histopathology and/or C-Urea Breath Test (UBT) and/or stool antigen testing. Successful eradication was documented by C-UBT, and/or stool antigen assay at least 4 weeks post-therapy. Compliance and side effects were recorded after completing treatment.A total of 45 patients (10 men, 35 women; mean age 52.6 years) have completed the treatment regimen with the success rate of 93% (95% confidence interval = 85-99%).
3.Comparison of intravenous pantoprazole and ranitidine in patients with dyspepsia presented to the emergency department: a randomized, double blind, controlled trial.
Senay E1, Eken C1, Yildiz M1, Yilmaz D1, Alkan E2, Akin M3, Serinken M4. World J Emerg Med. 2016;7(1):30-4. doi: 10.5847/wjem.j.1920-8642.2016.01.005.
BACKGROUND: This study aimed to compare pantoprazole, a proton-pomp inhibitors (PPIs), and ranitidine, a H2 receptor antagonists (H2RA), in ceasing dyspeptic symptoms in the emergency department (ED).
4.[In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Aksoy Gökmen A1, Girginkardeşler N, Kilimcioğlu AA, Şirin MC, Özbilgin A. Mikrobiyol Bul. 2016 Jan;50(1):133-9.
The current treatment of trichomoniasis is based on the use of 5-nitroimidazole derivatives. Although metronidazole is reliable, inexpensive and highly effective against anaerobic microorganisms and protozoa, the development of metronidazole-resistant T.vaginalis strains pose to an increasing problem. Nitroimidazoles are compounds having azomycin (2-nitroimidazole) chemical structure and are obtained from Streptomyces strains. Benzimidazole, which is found in the structure of proton pump inhibitors, is also present in the other components that have antiprotozoal activity. In this study, the in vitro susceptibility of T.vaginalis against metronidazole, ornidazole, and the proton pump inhibitors which are tested recently as antiprotozoal agents; pantoprazole and esomeprazole was investigated. For this purpose a clinical T.vaginalis strain which was formerly isolated and stored after cryopreservation process in our laboratory was used. Minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC) values of those agents against to this strain were determined in vitro by dilution method in 24-well cell culture plates.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 138530-94-6 Dexlansoprazole

Dexlansoprazole
(CAS: 138530-94-6)

Dexlansoprazole is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux dis...

CAS 73590-58-6 Omeprazole

Omeprazole
(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

CAS 335299-59-7 Tenatoprazole sodium

Tenatoprazole sodium
(CAS: 335299-59-7)

Tenatoprazole is a novel proton pump inhibitor which is similar to the chemical structure of omeprazole, a widely used proton pump inhibitor. Tenatoprazole belo...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

CAS 164579-32-2 Pantoprazole sodium hydrate

Pantoprazole sodium hydrate
(CAS: 164579-32-2)

Pantoprazole sodium hydrate is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or amel...

Chemical Structure

CAS 164579-32-2 Pantoprazole sodium hydrate

Quick Inquiry

Verification code

Featured Items